Both series yielded unique opportunities to investigate the prognostic value of the CD27−:CD27+ ratio as a surrogate of clonal T cell expansions in patients treated with regimens including lenalidomide, an IMID that requires tumor-reactive T cells to mediate its anti-MM effect25. Here, CD27 is linked to Miyoshi myopathy.